The net proceeds of the offering strengthen Adial’s balance sheet as it moves toward completion of the Company’s Phase 3 ONWARD™ trial.

A Charlottesville-based pharmaceutical company that recently began clinical trials of its Alzheimer’s treatment hit the stock market Thursday with an initial public offering it hopes will raise about $160 million.